Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Perjeta

02 3Phesgo

PharmaCompass

01

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 3,628

2018 Revenue in Millions : 2,856

Growth (%) : 27

blank

02

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 4,326

2019 Revenue in Millions : 3,924

Growth (%) : 10

blank

03

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 4,256

2020 Revenue in Millions : 4,116

Growth (%) : 2

blank

04

Brand Name : Phesgo

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Phesgo

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 366

2020 Revenue in Millions : 24

Growth (%) : 1,378

blank

05

Brand Name : Phesgo

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Phesgo

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 809

2021 Revenue in Millions : 366

Growth (%) : 121

blank

06

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 4,468

2021 Revenue in Millions : 4,256

Growth (%) : 5

blank

07

Brand Name : Phesgo

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Phesgo

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,299

2022 Revenue in Millions : 809

Growth (%) : 51

blank

08

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 4,372

2022 Revenue in Millions : 4,468

Growth (%) : -8

blank

09

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2014 Revenue in Millions : 181.60%

2013 Revenue in Millions :

Growth (%) :

blank

10

Brand Name : Perjeta

Pertuzumab

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Perjeta

arrow
2024 ACI Convention
Not Confirmed

Pertuzumab

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 927

2014 Revenue in Millions : 1,459

Growth (%) : 57%

blank